RBC Capital analyst Luca Issi maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $45 to $35.RBC Capital analyst Luca Issi maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price target from $45 to $35.
Recent Posts
- Spirit Airlines Gets Second Takeover Bid This Year: What Investors Should Know
- Sidus Space Stock Gains After Q4 Results, Clocks 95% Revenue Growth
- Apple App Store Analysis: This Streaming App Passed Disney+ And Netflix Over The Weekend Thanks To Wrestlemania
- $1000 Invested In Best Buy Co 10 Years Ago Would Be Worth This Much
- Here’s How Much $100 Invested In Activision Blizzard 20 Years Ago Would Be Worth Today
Recent Comments